{"contentid": 488221, "importid": NaN, "name": "Daiichi Sankyo drops out of vaccine alliance with Sanofi in Japan", "introduction": "Daiichi Sankyo today said that it will terminate its 2015 marketing alliance agreement for the Squarekids subcutaneous injection syringe, a tetravalent combination vaccine1 and its joint development agreement on pentavalent combination vaccine2 (VN-0105) with the local subsidiary of French pharma major Sanofi, effective March 31, 2021.", "content": "<p>Daiichi Sankyo (TYO: 4568) today said that it will terminate its 2015 marketing alliance agreement for the Squarekids subcutaneous injection syringe, a tetravalent combination vaccine1 and its joint development agreement on pentavalent combination vaccine2 (VN-0105) with the local subsidiary of French pharma major Sanofi (Euronext: SAN), effective March 31, 2021.</p>\n<p>Daiichi Sankyo, whose shares closed down 2.3% to 3,225 yen following the news, decided to suspend the production of Squarekids and its supply to the market due to a problem in the manufacture of pertussis vaccines, which it failed to resolve. In addition, Daiichi Sankyo will also end joint development efforts for VN-0105.</p>\n<p>Daiichi Sankyo will incur a 15 billion-yen (~$138 million) loss as it compensates Sanofi for the loss sustained from the termination of the two agreements. The cost will be recorded in the fourth quarter of fiscal year 2020, and the impact of this decision will appear in the company&rsquo;s consolidated financial results for this fiscal year at a later date.</p>\n<p>Daiichi Sankyo will continue working with Sanofi to enhance public health and prevent and treat diseases through the manufacture and supply of pharmaceutical products, including vaccines, thereby contributing to promoting people's health.</p>", "date": "2021-03-31 15:39:00", "meta_title": "Daiichi Sankyo drops out of vaccine alliance with Sanofi in Japan", "meta_keywords": "Daiichi Sankyo, Vaccine, Alliance, Terminated, Sanofi, Squarekids, VN-0105", "meta_description": "Daiichi Sankyo drops out of vaccine alliance with Sanofi in Japan", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-31 15:38:35", "updated": "2021-03-31 15:46:48", "access": NaN, "url": "https://www.thepharmaletter.com/article/daiichi-sankyo-drops-out-of-vaccine-alliance-with-sanofi-in-japan", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "daiichi-hq.jpg", "image2id": "daiichi-hq-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Vaccines", "topic_tag": "Asia Pacific, Deals, Focus On, Markets & Marketing, Production", "geography_tag": "France, Japan", "company_tag": "Daiichi Sankyo, Sanofi", "drug_tag": "Squarekids, VN-0105", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-31 15:39:00"}